Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871-1888. Abstract
Cardoso, F. Costa A, Senkus E, et al. ESO-ESMO 3rd international consensus guidelines for advanced breast cancer (ABC3). The Breast. 2017:31:244-259. Abstract
Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748-3757. Abstract
Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758-3767. Abstract
Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101-2109. Abstract
Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:4883-4890. Abstract
Chernozemsky I, Kalinov K, Tzekov H, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium (SABCS); December 13-16, 2007; Abstract 2102.
Robertson JF, Bondarento IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomized, double-blind, phase 3 trial. Lancet. 2016;388:2997-3005. Abstract
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-166. Abstract
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35. Abstract
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936. Abstract
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-1748. Abstract
Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH1: results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Presented at: American Society of Clinical Oncology 2016 Annual Meeting; June 3-7, 2016; Chicago, Illinois. Abstract 510.
Finn R, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women. Presented at: the European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract LBA15.
Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17:279-288. Abstract
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. Abstract
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870-884. Abstract
IBRANCE (palbociclib) [package insert] New York, NY:Pfizer;2016.

CPD

Optimizing Combination Endocrine Therapy in Advanced HR-Positive Breast Cancer

Authors: Nadia Harbeck, MD, PhD; Javier Cortés, MD, PhD; Thomas Bachelot, MD
CPD Released: 1/31/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 1/31/2018, 11:59 PM EST

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer.

The goal of this activity is to improve physicians' understanding regarding the use of cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy for treating HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients.

Upon completion of this activity, participants will:

Have greater competence regarding proper treatment approaches for postmenopausal HR-positive, HER2-negative metastatic breast cancer patients
Have greater competence related to managing adverse effects associated with the use of CDK4/6 inhibitors in combination with endocrine therapy
Have greater knowledge related to applying clinical trial data to clinical practice for the use of CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer patients

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderators

Nadia Harbeck, MD, PhD

Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich, Munich, Germany

Disclosures

Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc

Javier Cortés, MD, PhD

Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Disclosures

Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Thomas Bachelot, MD

Head, Medical Oncology Department, Centre Léon Bérard, Lyon, France

Disclosures

Disclosure: Thomas Bachelot, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceutical Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation Reviewed grants for clinical research from: Novartis Pharmaceutical Corporation; Roche

Steering Committee

Nadia Harbeck, MD, PhD

Disclosures

Disclosure: As listed above

Javier Cortés, MD, PhD

Disclosures

Disclosure: As listed above

Angelo Di Leo, MD, PhD

Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Disclosures

Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pierre Fabre; Roche

Stephen R.D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom

Disclosures

Disclosure: Stephen R.D. Johnston, MA, FRCP, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc; Puma Biotechnology
Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc

Xavier Pivot, MD, PhD

Professor, J Minjoz University Hospital, Besançon, France

Disclosures

Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

Sunil Verma, MD, MSEd, FRCPC

Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Disclosures

Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Editor

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Optimizing Combination Endocrine Therapy in Advanced HR-Positive Breast Cancer

Authors: Nadia Harbeck, MD, PhD; Javier Cortés, MD, PhD; Thomas Bachelot, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 1/31/2017

Valid for credit through: 1/31/2018, 11:59 PM EST

processing....

CPD Information Download Slides

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderators

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Thomas Bachelot, MD

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, MA, FRCP, PhD

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editor

Deborah Middleton, MS

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

CPD

Optimizing Combination Endocrine Therapy in Advanced HR-Positive Breast Cancer

Target Audience and Goal Statement

Disclosures

Moderators

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Thomas Bachelot, MD

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, MA, FRCP, PhD

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editor

Deborah Middleton, MS

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Optimizing Combination Endocrine Therapy in Advanced HR-Positive Breast Cancer